Professional Documents
Culture Documents
symptoms of urinary tract infection, such as dysuria, urinary frequency, suprapubic pain,
flank pain and fever. For clean-catch urine samples, a positive urine culture as indicated
by the growth of bacteria greater than 100.000 CFUs/ml is suggestive of UTI; growth of
1.000 100.000 CFUs/ml may still indicate UTI, especially for specimen taken at
cystoscopy or other invasive procedurs. Growth of 2 or more different bacteria or
polymicrobial growth is likely to the result of contamination
timbul beberapa minggu setelah seseorang terinfeksi virus HIV. Sindrom ini menyerupai
gejala flu (flu like syndrome) atau menyerupai infeksi mononucleosis (mononucleosis like
syndrome) . Pada fase ini viral load cukup tinggi sehingga sangat infeksius, namun
belum terbentuk antibodi yang cukup untuk menimbulkan tes antibody HIV positif,
sehingga sering kali berakibat tidak terdiagnosis dengan pemeriksaan laboratorium yang
rutin. Keadaan ini juga disebut infeksi HIV primer dimana secara laboratorium,
fase
infeksi akut ini ditandai dengan terdeteksinya RNA virus HIV atau antigen p24 dalam
darah dan antibodi HIV negatif. Diagnosis akut retroviral syndrome
tantangan karena belum dapat terdiagnosis dengan baik, padahal
masih menjadi
infeksi HIV akut
merupakan saat yang penting untuk mencegah perjalanan penyakit lebih lanjut, misalnya
pada
ibu hamil dan bayi-bayi yang lahir dari ibu HIV positif. Sindrom ARVS yang
merupakan gejala infeksi HIV primer timbul setelah 6 minggu infeksi. Gejala infeksi akut
biasanya sembuh sendiri tanpa gejala sisa.
WHEN USE ANTI RETRO VIRAL (ARV) IN ACUTE RETROVIRAL SYNDROME (ARVS)
?
Made Susila Utama, Tuti Parwati Merati
Division of Tropical and Infectious Disease
Department of Internal Medicine
Udayana University School of Medicine- Sanglah Hospital Denpasar
Acute human immunodeficiency virus (HIV) infection, also known as primary HIV
infection or acute retroviral syndrome (ARVS), is the period just after initial HIV infection,
generally before seroconversion. It is estimated that 40-90% patients with primary HIV
infection experience ARVS. The development of ARVS typically coincides with high level
viremia and the hosts initial immunological response. Symptoms typically occur 2-6 week
after exposure and last for 14 days but may persist as long as 10 weeks. The clinical
features of acute retroviral syndrome are non-specific. An acute infectious mononucleosislike illness occurs in up to 93% of patients but many organ systems can be affected,
causing a wide array of symptoms and signs mimicking other clinical entities.
Constitutional symptoms of fever, malaise or fatigue, anorexia, weight loss, maculopapular
skin rash, mucosal membrane ulcerations, pharyngitis and diffuse lymphadenopathy are
common.
When clinicians suspect acute infection (e.g., in a patient with a report of recent risk
behavior in association with symptoms and signs of the acute retroviral syndrome), a test
for HIV RNA should be performed. High levels of HIV RNA detected in plasma through use
of sensitive amplification assays (PCR, bDNA, or NASBA), in combination with a negative
or indeterminate HIV antibody test, support the diagnosis of acute HIV infection. Low-level
positive PCR results (<5000 copies/mL) are often not diagnostic of acute HIV infection and
should be repeated to exclude a false-positive result. HIV RNA levels tend to be very high
in acute infection; however, a low value may represent any point on the upward or
downward slope of the viremia associated with acute infection. Plasma HIV RNA levels
during seroconversion do not appear significantly different in patients who have acute
symptoms versus those who are asymptomatic. Viremia occurs approximately 2 weeks
prior to the detection of a specific immune response. Patients diagnosed with acute HIV
infection by HIV RNA testing still require antibody testing with confirmatory Western blot 3
to 6 weeks later.
Symptoms of primary HIV infection can usually be managed in the primary care
setting by the general practitioner. Decisions about antiretroviral therapy need to be made
in conjunction with an HIV experienced clinician. Rational for ARV therapy in ARVS such
as to reduce the risk of viral transmission, preserve HIV-specific immune function,
including promoting the survival of CD4 cells that are involved in the initial response to HIV
infection, suppress the initial burst of viral replication and decrease the magnitude of viral
dissemination, potentially lower the initial viral setpoint, which may ultimately affect the rate
of disease progression, potentially reduce the emergence of viral mutations as a result of
the suppression of viral replication. Disadvantage of ARV in ARVS, adverse effects on
quality of life as a result of drug toxicities and complex treatment regimens, potential for
the development of drug resistance if therapy fails due to non adherence or to insufficient
suppression of viral replication, which may limit future treatment options, earlier
commitment to lifetime ARV therapy, less time to educate the patient about ARV therapy
and insufficient data regarding effectiveness of early treatment. In the absence of
randomized controlled trials data demonstrating clinical benefit of antiretroviral therapy
intervention in primary HIV infection, clinical guidelines remain unclear. Intervention seems
a logical strategy to counter the high viraemia, enhanced onward transmissibility, and
immunological destruction which occurs during primary HIV infection. The nature, duration
and timing of that intervention after HIV acquisition remains unknown. The clinician and
the patient should be aware that therapy for acute HIV infection is primarily based on
theoretical considerations, and the potential benefits should be weighed against the
potential risks.